Pfizer Inc
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Corporate / Unallocated Reconciling Item by Quarter
Corporate / Unallocated Reconciling Item — Acquisition-related costs pretax impact ($M) ($M)
Pfizer Corporate / Unallocated Reconciling Item: -$669M in Q2 2026, up 97.9% from a year earlier.
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K Note 17 — Segment Reporting (ASU 2023-07 Significant Segment Expenses).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Corporate / Unallocated Reconciling Item — Acquisition-related costs pretax impact ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 28, 2026 | -669 | +97.9% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2026 | Mar 29, 2026 | -504 | +78.7% | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2025 | Dec 31, 2025 | -471 | +35.3% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2025 | Sep 28, 2025 | -194 | -58.3% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 29, 2025 | -338 | -45.2% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2025 | Mar 30, 2025 | -282 | -44.5% | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2024 | Dec 31, 2024 | -348 | -68.2% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2024 | Sep 29, 2024 | -465 | +104.8% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | -617 | +59.4% | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2024 | Mar 31, 2024 | -508 | +211.7% | Form 10-Q (filed 2025-05-05) ↗ |
| Q4 2023 | Dec 31, 2023 | -1,096 | +118.8% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2023 | Oct 1, 2023 | -227 | +266.1% | Form 10-Q (filed 2024-11-04) ↗ |
| Q2 2023 | Jul 2, 2023 | -387 | +372.0% | Form 10-Q (filed 2024-08-05) ↗ |
| Q1 2023 | Apr 2, 2023 | -163 | -12.8% | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2022 | Dec 31, 2022 | -501 | +300.8% | Form 10-K (filed 2025-02-27) ↗ |
| Q3 2022 | Oct 2, 2022 | -62 | +51.2% | Form 10-Q (filed 2023-11-08) ↗ |
| Q2 2022 | Jul 3, 2022 | -82 | +141.2% | Form 10-Q (filed 2023-08-09) ↗ |
| Q1 2022 | Apr 3, 2022 | -187 | -406.6% | Form 10-Q (filed 2023-05-10) ↗ |
| Q4 2021 | Dec 31, 2021 | -125 | – | Form 10-K (filed 2024-02-22) ↗ |
| Q3 2021 | Oct 3, 2021 | -41 | – | Form 10-Q (filed 2022-11-09) ↗ |
| Q2 2021 | Jul 4, 2021 | -34 | – | Form 10-Q (filed 2022-08-10) ↗ |
| Q1 2021 | Apr 4, 2021 | 61 | – | Form 10-Q (filed 2022-05-11) ↗ |
Cite this data
StockData. (2026). Pfizer Corporate / Unallocated Reconciling Item ($M), quarterly Q1 2021–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/seg-ebt-recon-acq
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.